China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its biosimilar version of Novo Nordisk’s (NYSE: NVO) Ryzodeg (insulin degludec, insulin aspart), intended for the treatment of adults with type 2 diabetes.
The drug in question is a compound preparation comprising 70% insulin degludec and 30% insulin aspart. Insulin degludec specifically binds to human insulin receptors, exerting pharmacological effects akin to human insulin. Insulin aspart is noted for its faster onset of action compared to soluble human insulin.- Flcube.com
